A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA (Anti-C5) in Combination With EYLEA in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy

Trial Profile

A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA (Anti-C5) in Combination With EYLEA in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Aflibercept (Primary) ; Avacincaptad pegol (Primary)
  • Indications Polypoidal choroidal vasculopathy
  • Focus Adverse reactions
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 11 Dec 2017 Status changed from planning to recruiting.
    • 08 Nov 2017 Accordng to an OphthoTech Corporation media release, initial top-line data is expected to be available during the second half of 2019.
    • 31 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top